Lung Cancer (Suspected or Confirmed)

4

Review clinical trials related to Lung Cancer (Suspected or Confirmed). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Volunteers.

Lung cancer remains the leading cause of cancer-related death in the UK, with over 35,000 deaths annually and most cases diagnosed at a late stage. Current screening programmes using low-dose CT scans target only high-risk individuals, missing around 30% of lung cancer cases, including many women and never-smokers. There is no simple, non-invasive tool to help triage patients with persistent respiratory symptoms who fall outside formal screening criteria. Inflammacheck® measures hydrogen peroxide and other breath biomarkers linked to airway inflammation and oxidative stress. Preliminary studies (VICTORY and ExPeL) have shown strong diagnostic performance for distinguishing lung cancer from other respiratory conditions. VICTORY 2 aims to validate and refine the AI model supporting Inflammacheck®, enabling accurate, rapid, and affordable triage for suspected lung cancer in NHS settings.

Participants needed: 140
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Portsmouth Hospitals NHS TrustUpdated: May 8, 2026Locations: 1
Eligibility criteria

Group A: Lung cancer confirmed by multidisciplinary team (MDT) diagnosis. [+5]

1. Active respiratory infection (e.g., tuberculosis, bronchopneumonia) other tha...

Status: Not yet recruiting

One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation

Using RBS as the navigation and treatment platform, precisely navigate to the target lesion. Utilize r-EUBS and nCLE to identify the lesion, and when the confocal AI model recognizes the lesion as malignant, perform a biopsy. Subsequently, under the guidance of OBCT, carry out ablation treatment of the lesion.

Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Guangzhou Medical UniversityUpdated: Apr 13, 2026
Eligibility criteria

Age ≥18 years, male or female. [+3]

Diffuse bilateral lung lesions unresponsive to ablation. [+11]

Status: Not yet recruiting

Effect of a Music Intervention in Reducing Distress and Pain in Patients With Lung Cancer Undergoing Mini-invasive Surgery

This study aims at evaluating whether music therapy intervention is effective in decreasing psychological (distress) and physical symptoms (pain) in patients with suspected or diagnosed lung cancer undergoing minimally invasive lung surgery.

Participants needed: 74
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Oncology Institute of Southern SwitzerlandUpdated: Nov 19, 2025Locations: 1
Eligibility criteria

Suspected or confirmed diagnosis of lung cancer [+3]

Endocrinological disorders involving cortisol axis [+5]

Status: Not yet recruiting

Monarch Robotic Bronchoscopy for Lung Nodule ICG Dye Marking Before VATS

This is a single-center, prospective, single-arm clinical study conducted at Beijing Cancer Hospital to evaluate the effectiveness, safety, and learning curve of preoperative indocyanine green (ICG) dye marking mixed with iodinated contrast agent under Monarch Robotic Assisted Bronchoscopy (RAB) with Cone-Beam CT (CBCT) for small pulmonary nodules that are difficult to locate during video-assisted thoracic surgery (VATS) sublobectomy. Eligible patients will undergo RAB localization immediately followed by VATS in the same operative session. The primary endpoints include the success rate of localization, effective localization, and VATS sublobar resection. Secondary endpoints include navigation success rate, operation times, reaching depth, complication rates, and health economic outcomes. The learning curve will be analyzed using the cumulative sum (CUSUM) method. A total of 50 patients will be enrolled and followed up for 14 days postoperatively.

Participants needed: 50
Trial details
Age: 18-80Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Sep 17, 2025
Eligibility criteria

Age 18-80 years [+4]

Contraindications to bronchoscopy/anesthesia [+5]